|
The effects of the first in class steroid sulfatase inhibitor Irosustat on FLT uptake and Ki67 in estrogen receptor positive early breast cancer: Results of the perioperative IPET study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (Inst); Eisai (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Atossa Genetics |
Speakers' Bureau - Pfizer |
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |